The IGBMC spinout was set up by Satt Conectus and is now seeking a listing in the US with a price range of $15 to $17.

Dynacure, the France-based muscular disease treatment developer spun out of Institute of Genetic and Molecular and Cellular Biology (IGBMC), has set the range for an initial public offering that could raise up to $107m. The company plans to offer 6.3 million American depository shares (ADSs), each representing one ordinary share, at a price range of…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.